Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the comprehensive launch of the Axonics F15 across the United States. The newly developed, long-lived, fully recharge-free sacral neuromodulation (SNM) system received FDA approval in March.

“The Axonics recharge-free system is a welcome advancement for patients suffering from bladder and bowel dysfunction,” said Taylor Moore, M.D., board-certified urologist at Arkansas Urology. “My initial implants of the new device have gone well, with low amplitudes achieved at the time of implant suggesting longevity in the body of around 20 years. Clinical outcomes with the Axonics rechargeable SNM system have exceeded our expectations and we anticipate similar results with the Axonics F15. We are pleased to now offer patients a non-rechargeable option that provides significant longevity in the body, constant current stimulation, and a remote control that is recharge-free and easy for patients to use.”

About Axonics F15

  • INS type: primary cell battery
  • INS longevity: functional life has been validated for over 15 years at typical stimulation parameters and over 20 years at lower energy settings
  • INS volume: 10 cubic centimeters (20% smaller than the market’s other non-rechargeable SNM device)
  • Stimulation: constant current automatically adjusts stimulation output
  • Tined lead: universal tined lead compatible with both recharge-free and rechargeable Axonics systems
  • MRI compatibility: full body with 1.5T and 3.0T whole-body scanners
  • Patient remote control: intuitive, recharge-free key fob featuring SmartMRI technology
  • Programming: proprietary algorithm recommends optimal stimulation parameters based on intraoperative responses

Raymond W. Cohen, CEO of Axonics, said, “Physician response to the Axonics F15 has been overwhelmingly positive. Our sales team is now armed with a complete portfolio of SNM products that, along with our national DTC campaign, will contribute to Axonics achieving its mission of treating more adults suffering from incontinence. We remain confident that our commitment to innovation, quality, and providing physicians and patients strong support will continue to drive SNM market expansion and advance Axonics on its path to market leadership.”

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.

Axonics’ sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

"We are pleased to now offer patients a non-rechargeable option that provides significant longevity in the body, constant current stimulation, and a remote control that is recharge-free and easy for patients to use."

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.